{
    "Symbol": "SRPT",
    "AssetType": "Common Stock",
    "Name": "Sarepta Therapeutics Inc",
    "Description": "Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.",
    "CIK": "873303",
    "Exchange": "NASDAQ",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "PHARMACEUTICAL PREPARATIONS",
    "Address": "215 FIRST STREET, SUITE 415, CAMBRIDGE, MA, US",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2024-03-31",
    "MarketCapitalization": "13516903000",
    "EBITDA": "-52995000",
    "PERatio": "332.56",
    "PEGRatio": "159.25",
    "BookValue": "10.17",
    "DividendPerShare": "None",
    "DividendYield": "None",
    "EPS": "0.43",
    "RevenuePerShareTTM": "14.95",
    "ProfitMargin": "0.012",
    "OperatingMarginTTM": "0.0844",
    "ReturnOnAssetsTTM": "-0.0189",
    "ReturnOnEquityTTM": "0.0202",
    "RevenueTTM": "1403300000",
    "GrossProfitTTM": "-78066000",
    "DilutedEPSTTM": "0.43",
    "QuarterlyEarningsGrowthYOY": "0",
    "QuarterlyRevenueGrowthYOY": "0.631",
    "AnalystTargetPrice": "196.69",
    "AnalystRatingStrongBuy": "10",
    "AnalystRatingBuy": "10",
    "AnalystRatingHold": "3",
    "AnalystRatingSell": "0",
    "AnalystRatingStrongSell": "0",
    "TrailingPE": "332.56",
    "ForwardPE": "35.21",
    "PriceToSalesRatioTTM": "9.28",
    "PriceToBookRatio": "13.43",
    "EVToRevenue": "9.06",
    "EVToEBITDA": "-24.82",
    "Beta": "0.884",
    "52WeekHigh": "173.25",
    "52WeekLow": "55.25",
    "50DayMovingAverage": "138.75",
    "200DayMovingAverage": "119.08",
    "SharesOutstanding": "94524000",
    "DividendDate": "None",
    "ExDividendDate": "None"
}